Latin America Pharma

Business

Idorsia's Latin American Gambit: QUVIVIQ Deal with EMS Signals Strategic Shift Amid Pipeline Scrutiny

Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.

Feb 2, 2026

Business

Latin America's Economic Crossroads: Navigating the Surge of Chinese Imports

As Chinese exports, from electric vehicles to e-commerce goods, reshape Latin American markets, governments and industries grapple with the dual pressures of affordable consumer goods and strained local manufacturing, forcing a delicate recalibration of trade policies and regional alliances.

Feb 2, 2026

World

Latin America's Balancing Act: Navigating the Surge of Chinese Imports

As Chinese exports, from electric vehicles to e-commerce parcels, flood Latin American markets, nations across the region are grappling with the dual pressures of protecting domestic industries and maintaining vital economic ties with Beijing.

Feb 2, 2026

World

Latin America's Trade Dilemma: Chinese EVs and E-commerce Goods Reshape Markets, Prompting Protectionist Pushback

A surge of competitively priced Chinese electric vehicles and consumer goods is rapidly transforming Latin American markets, forcing governments from Mexico to Brazil to enact new tariffs and trade defenses to shield domestic industries from the influx.

Feb 2, 2026

World

Latin America's Trade Dilemma: Balancing Consumer Demand and Industry Survival Amid Chinese Export Surge

As Chinese exports, from electric vehicles to e-commerce parcels, flood Latin American markets, governments are walking a tightrope between protecting domestic industries and satisfying consumer demand for affordable goods, all while navigating deepening economic ties with Beijing.

Feb 2, 2026

Business

Bank of America Lifts Target on Xencor Amid Broader Biotech Sector Optimism

Bank of America has raised its price target for clinical-stage biopharma firm Xencor (XNCR), highlighting a cautiously improving landscape for the sector driven by data catalysts, M&A, and capital access.

Jan 30, 2026

Business

Bank of America Bullish on Apellis, Upgrades to 'Buy' on Strong Drug Launch and Kidney Disease Prospects

Bank of America has upgraded Apellis Pharmaceuticals (APLS) to 'Buy,' citing robust early adoption of its drug Empaveli and significant undervaluation of its potential in treating rare kidney diseases, despite a more cautious outlook from Wells Fargo.

Jan 30, 2026

Business

Rhythm Pharmaceuticals: The Under-the-Radar Biotech Outpacing Tech Giants

While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.

Feb 2, 2026

Business

Terns Pharma Secures Global Rights for Key Drug, Fueling Expansion Ambitions Beyond China

Terns Pharmaceuticals has restructured a key licensing deal with China's Hansoh, gaining exclusive worldwide rights for its TERN-701 oncology drug outside Greater China. The strategic move, coupled with a recent analyst price target surge, signals the company's aggressive push into international markets.

Feb 2, 2026

Business

Day One Biopharmaceuticals: Surging Momentum Raises Valuation Questions Amid High-Stakes Pipeline

Shares of Day One Biopharmaceuticals (NASDAQ: DAWN) have surged over 50% in the last three months, reigniting debate over its fair value and the risks tied to its lead drug OJEMDA and a pivotal upcoming data readout.

Jan 31, 2026

Business

American Express Shares Dip on Q4 Miss, But Premium Strategy Fuels Optimistic 2026 Outlook

American Express reported fourth-quarter earnings that narrowly missed analyst forecasts, yet a modest stock decline reflects investor confidence in its robust guidance and the sustained momentum of its high-end cardmember base.

Jan 30, 2026

Business

American Express Caps 2025 with Record Revenue, Eyes Continued Premium Growth in 2026

American Express reported a 10% revenue surge to $72 billion for 2025, driven by strong premium card demand and disciplined credit. Executives project 9-10% growth for 2026, betting on younger customers and strategic tech investments to sustain momentum.

Jan 30, 2026

Business

American Express Caps Strong 2025 with Record Revenues, Eyes Sustained Premium Growth in 2026

American Express reported record full-year revenues of $72 billion for 2025, driven by robust card member spending and a strategic shift towards premium products. The company forecasts continued momentum for 2026, targeting 9-10% revenue growth and a significant dividend hike, while navigating a competitive landscape and macroeconomic uncertainties.

Jan 30, 2026

Business

Plains All American Doubles Down on Crude with EPIC Pipeline Deal, Sparking Investor Debate

Plains All American Pipeline's strategic pivot—selling its Canadian NGL unit for $3.8 billion to fund the acquisition of the EPIC Crude Oil Pipeline—has sharpened its focus on oil transportation. While a 10% distribution hike signals confidence, analyst downgrades and heightened options volatility ahead of earnings reveal deep divisions over the company's risk-reward profile.

Jan 30, 2026

Business

American Airlines to Compensate Crews After Winter Storm Strandings, Amid Union Pressure

American Airlines begins compensating flight attendants left without accommodations during Winter Storm Fern, as the union accuses management of contract violations and calls for accountability.

Feb 2, 2026

Business

Guardian Pharmacy Services: Is the Stock Fairly Valued After Recent Gains?

A deep dive into Guardian Pharmacy Services (NYSE:GRDN) using a discounted cash flow model suggests its current share price is hovering close to its estimated intrinsic value. While the analysis provides a quantitative benchmark, investors are cautioned that valuation is just one piece of the puzzle in a complex and regulated healthcare sector.

Feb 2, 2026

Business

Merck's Meteoric Rise: Is the Pharma Giant Still a Bargain After Years of Stellar Gains?

Merck & Co. shares have delivered impressive multi-year returns, climbing over 80% in the past five years. Yet, a deep dive into its valuation metrics suggests the market may still be underestimating the pharmaceutical leader's intrinsic value, presenting a potential opportunity for investors.

Feb 2, 2026

Business

New Gold Shareholders Greenlight Coeur Mining Takeover, Forging a North American Precious Metals Powerhouse

New Gold Inc. shareholders have overwhelmingly approved the planned acquisition by Coeur Mining, a move set to create a leading, diversified precious metals producer focused entirely in North America. The deal, valued through a share swap, is anticipated to close in mid-2026.

Feb 2, 2026

Business

Takeda's Stock Surge Puts Valuation in Spotlight: Is the Pharma Giant Overpriced or Undervalued?

Takeda Pharmaceutical's (TSE:4502) recent share price rally has ignited a debate among investors. With the stock closing at ¥5,242, analysts are divided on its true worth, presenting a complex picture of fair value signals and future growth prospects.

Feb 2, 2026

Business

Bank of America Navigates Legal Storm and Digital Future Amid Epstein Lawsuit and Stablecoin Policy Talks

As a federal judge advances a lawsuit tying Bank of America to Jeffrey Epstein's sex trafficking network, the financial giant simultaneously positions itself at the forefront of stablecoin regulation discussions with Coinbase and the White House, creating a complex risk-and-opportunity landscape for investors.

Feb 2, 2026